On the pathogenesis of Bartter's syndrome: report of studies in a patient with this disorder.
A 25 year old male with features typical of Bartter's syndrome is described. Studies were performed to evaluate the pathogenesis of this disorder. In response to oral water loading the subject excreted free water normally. Normal renal sodium conservation was documented. Autonomy of the reninangiotensin-aldosterone system was excluded by demonstrating appropriate directional changes in plasma renin activity and aldosterone excretion in response to alterations in sodium and potassium intake. During aminoglutethimide inhibition of aldosterone synthesis the subject was able to maintain potassium balance at a normal serum potassium concentration on a potassium intake of 130 mEq/day which suggests that aldosterone is the major cause of the potassium wasting. Decreased vascular responses to intra-arterial infusions of angiotensin II and norepinephrine were documented in the absence of extracellular volume depletion. These findings argue against tachyphylaxis as the explanation for the vascular insensitivity and implicate a defect at some step in the sequence between agonist-receptor interaction and the contractile response. It is proposed that the vascular defect plays a primary role in the pathogenesis of the hyperreninemia by interrupting pressure-mediated inhibition of renin secretion and/or impairing direct feedback inhibition of renin secretion by angiotensin II. A unique finding in our case was the lack of a postural influence on plasma renin activity and plasma aldosterone. An accentuated plasma aldosterone circadian rhythm was observed independent of plasma renin activity and plasma potassium concentration. Dexamethasone suppression of ACTH reduced but did not abolish the circadian rhythm. Thus some factor in addition to plasma renin activity, potassium and ACTH appears to influence aldosterone secretion in this patient.
D000328:Adult; D000450:Aldosterone / Q000097:blood / Q000652:urine; D000804:Angiotensin II / Q000494:pharmacology; D001477:Bartter Syndrome / Q000097:blood / Q000209:etiology*; D001783:Blood Flow Velocity; D001794:Blood Pressure / Q000187:drug effects; D001806:Blood Urea Nitrogen; D001810:Blood Volume / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004573:Electrolytes / Q000097:blood; D006801:Humans; D006929:Hyperaldosteronism / Q000209:etiology*; D007671:Kidney Concentrating Ability; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D011188:Potassium / Q000652:urine; D011433:Propranolol / Q000627:therapeutic use; D012083:Renin / Q000097:blood; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage; D014655:Vascular Resistance / Q000187:drug effects
D004573:Electrolytes; D012462:Saline Solution, Hypertonic; D000804:Angiotensin II; D000450:Aldosterone; D011433:Propranolol; D003404:Creatinine; D012083:Renin; D011188:Potassium; D009638:Norepinephrine